Protagonist Therapeutics
PTGX
PTGX
148 hedge funds and large institutions have $1.67B invested in Protagonist Therapeutics in 2021 Q4 according to their latest regulatory filings, with 35 funds opening new positions, 59 increasing their positions, 35 reducing their positions, and 19 closing their positions.
New
Increased
Maintained
Reduced
Closed
Holders
148
Holders Change
+16
Holders Change %
+12.12%
% of All Funds
2.29%
Holding in Top 10
8
Holding in Top 10 Change
+6
Holding in Top 10 Change %
+300%
% of All Funds
0.12%
New
35
Increased
59
Reduced
35
Closed
19
Calls
$46.3M
Puts
$19.9M
Net Calls
+$26.3M
Net Calls Change
+$15.6M
Top Buyers
| 1 |
EC
EcoR1 Capital
San Francisco,
California
|
$90.3M |
| 2 |
RI
RTW Investments
New York
|
$88.9M |
| 3 |
State Street
Boston,
Massachusetts
|
$87.9M |
| 4 |
WP
Woodline Partners
San Francisco,
California
|
$16.9M |
| 5 |
SC
Samlyn Capital
New York
|
$15.4M |
Top Sellers
| 1 |
Point72 Asset Management
Stamford,
Connecticut
|
$82.8M |
| 2 |
FCM
Farallon Capital Management
San Francisco,
California
|
$65.6M |
| 3 |
Morgan Stanley
New York
|
$3.67M |
| 4 |
Voloridge Investment Management
Jupiter,
Florida
|
$6.28M |
| 5 |
Goldman Sachs
New York
|
$4.23M |
